These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25289928)

  • 61. Evidence for the role of osteocytes in the initiation of targeted remodeling.
    Heino TJ; Kurata K; Higaki H; Väänänen HK
    Technol Health Care; 2009; 17(1):49-56. PubMed ID: 19478405
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pulsed electromagnetic fields regulate osteocyte apoptosis, RANKL/OPG expression, and its control of osteoclastogenesis depending on the presence of primary cilia.
    Wang P; Tang C; Wu J; Yang Y; Yan Z; Liu X; Shao X; Zhai M; Gao J; Liang S; Luo E; Jing D
    J Cell Physiol; 2019 Jul; 234(7):10588-10601. PubMed ID: 30422320
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Positive regulation of osteoclastic differentiation by growth differentiation factor 15 upregulated in osteocytic cells under hypoxia.
    Hinoi E; Ochi H; Takarada T; Nakatani E; Iezaki T; Nakajima H; Fujita H; Takahata Y; Hidano S; Kobayashi T; Takeda S; Yoneda Y
    J Bone Miner Res; 2012 Apr; 27(4):938-49. PubMed ID: 22190281
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
    Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J
    FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis.
    Kramer I; Halleux C; Keller H; Pegurri M; Gooi JH; Weber PB; Feng JQ; Bonewald LF; Kneissel M
    Mol Cell Biol; 2010 Jun; 30(12):3071-85. PubMed ID: 20404086
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
    Kogawa M; Wijenayaka AR; Ormsby RT; Thomas GP; Anderson PH; Bonewald LF; Findlay DM; Atkins GJ
    J Bone Miner Res; 2013 Dec; 28(12):2436-48. PubMed ID: 23737439
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
    Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
    Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
    [TBL] [Abstract][Full Text] [Related]  

  • 68. RANKL (Receptor Activator of NFκB Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice.
    Fujiwara Y; Piemontese M; Liu Y; Thostenson JD; Xiong J; O'Brien CA
    J Biol Chem; 2016 Nov; 291(48):24838-24850. PubMed ID: 27733688
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor κB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading.
    Plotkin LI; Gortazar AR; Davis HM; Condon KW; Gabilondo H; Maycas M; Allen MR; Bellido T
    J Biol Chem; 2015 Jul; 290(31):18934-42. PubMed ID: 26085098
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells.
    Liu S; Fan Y; Chen A; Jalali A; Minami K; Ogawa K; Nakshatri H; Li BY; Yokota H
    Cancer Res; 2018 Jul; 78(14):3865-3876. PubMed ID: 29769195
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading.
    You L; Temiyasathit S; Lee P; Kim CH; Tummala P; Yao W; Kingery W; Malone AM; Kwon RY; Jacobs CR
    Bone; 2008 Jan; 42(1):172-9. PubMed ID: 17997378
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Vibration enhances osteoclastogenesis by inducing RANKL expression via NF-κB signaling in osteocytes.
    Sakamoto M; Fukunaga T; Sasaki K; Seiryu M; Yoshizawa M; Takeshita N; Takano-Yamamoto T
    Bone; 2019 Jun; 123():56-66. PubMed ID: 30902792
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
    Buckle CH; De Leenheer E; Lawson MA; Yong K; Rabin N; Perry M; Vanderkerken K; Croucher PI
    PLoS One; 2012; 7(8):e41127. PubMed ID: 22952578
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.
    Delgado-Calle J; Anderson J; Cregor MD; Condon KW; Kuhstoss SA; Plotkin LI; Bellido T; Roodman GD
    Leukemia; 2017 Dec; 31(12):2686-2694. PubMed ID: 28529307
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Osteocyte TSC1 promotes sclerostin secretion to restrain osteogenesis in mice.
    Liu W; Wang Z; Yang J; Wang Y; Li K; Huang B; Yan B; Wang T; Li M; Zou Z; Yang J; Xiao G; Cui ZK; Liu A; Bai X
    Open Biol; 2019 May; 9(5):180262. PubMed ID: 31088250
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mechanobiological osteocyte feedback drives mechanostat regulation of bone in a multiscale computational model.
    Martin M; Sansalone V; Cooper DML; Forwood MR; Pivonka P
    Biomech Model Mechanobiol; 2019 Oct; 18(5):1475-1496. PubMed ID: 31087221
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
    Terpos E; Christoulas D; Katodritou E; Bratengeier C; Gkotzamanidou M; Michalis E; Delimpasi S; Pouli A; Meletis J; Kastritis E; Zervas K; Dimopoulos MA
    Int J Cancer; 2012 Sep; 131(6):1466-71. PubMed ID: 22052418
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The pathogenesis of the bone disease of multiple myeloma.
    Edwards CM; Zhuang J; Mundy GR
    Bone; 2008 Jun; 42(6):1007-13. PubMed ID: 18406675
    [TBL] [Abstract][Full Text] [Related]  

  • 79. RANKL subcellular trafficking and regulatory mechanisms in osteocytes.
    Honma M; Ikebuchi Y; Kariya Y; Hayashi M; Hayashi N; Aoki S; Suzuki H
    J Bone Miner Res; 2013 Sep; 28(9):1936-49. PubMed ID: 23529793
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Osteocyte necrosis triggers osteoclast-mediated bone loss through macrophage-inducible C-type lectin.
    Andreev D; Liu M; Weidner D; Kachler K; Faas M; Grüneboom A; Schlötzer-Schrehardt U; Muñoz LE; Steffen U; Grötsch B; Killy B; Krönke G; Luebke AM; Niemeier A; Wehrhan F; Lang R; Schett G; Bozec A
    J Clin Invest; 2020 Sep; 130(9):4811-4830. PubMed ID: 32773408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.